Rifaximin in Patients With Diabetic Gastroparesis
| Condition | Crohn Disease, Diabetic Gastroparesis |
|---|---|
| Phase | Phase 2 |
| Sponsor | Mayo Clinic |
| Status | Terminated |
| Enrollment | 5 participants |
| Interventions | Rifaximin |
| Start date | Jun 14, 2019 |
| Completion date | Apr 8, 2025 |
| Results posted | Jun 22, 2026 |
Summary
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
Improvement in Bloating Based on Overall Questionnaire Scoring
| Intervention Treatment | 4 participants |
|---|---|
| Placebo Group | 1 participants |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Act — Janssen Research & Development, LLC
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severe — Janssen Research & Development, LLC
- A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn' — Janssen Research & Development, LLC
- A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Partic — Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease — Celularity Incorporated
- Loss of RESponse to Ustekinumab Treated by Dose Escalation — Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW